Search results
Results from the WOW.Com Content Network
Drug Trade name Type Main indications Company Sales (USD millions/year) ∆ vs 2014 1 Adalimumab: Humira Biologic Rheumatoid arthritis: AbbVie Inc. 14,012 1,469 2 Ledipasvir/sofosbuvir: Harvoni Small molecule Hepatitis C: Gilead Sciences: 13,864 11,737 3 Etanercept: Enbrel Biologic Rheumatoid arthritis: Amgen. Pfizer. 8,697 4,009 4 Infliximab ...
SAGES 2020-2021 SLATE OF OFFICERS PRESIDENT - Liane S. Feldman, MD PRESIDENT-ELECT - John D. Mellinger, MD 1st VICE PRESIDENT - Robert Lim, MD 2nd VICE PRESIDENT - Patricia Sylla, MD SECRETARY - Brent Matthews, MD TREASURER - Chris Schlachta, MD
Sharma was born in Chandigarh, India.He graduated with a MBBS from M.S. University of Baroda in 1991 [3] and from the University of Louisville School of Medicine in 1992. [4] He completed his internal medicine residency at the Medical College of Wisconsin in Milwaukee and his gastroenterology fellowship at the University of Arizona in Tucson.
Sun Pharmaceutical Industries Ltd. was established by Dilip Shanghvi in 1983 in Calcutta, West Bengal with five psychiatry products and a two-person marketing team. Today it is ranked number one in share of prescriptions with 12 classes of doctors in India and a market leader in Psychiatry, Neurology, Cardiology, Orthopaedics, Gastroenterology, Nephrology, Diabetology, Dermatology, Urology ...
A newer PCAB vonoprazan with a faster and longer lasting action than revaprazan, and PPIs has been marketed in Japan (2013), Russia (2021), and the US (2023). [4] [5] [6] PPIs are among the most widely sold medications in the world. The class of proton-pump inhibitor medications is on the World Health Organization's List of Essential Medicines.
As a cyberattack continues to disrupt insurance processing at pharmacies across the United States, people like Mara Furlich are facing a stark choice: Pay, at least initially, out of pocket for ...
In 2021, she was inducted into the Academy of Science, Engineering and Medicine of Florida for "her research in advancing understanding of therapeutic drug monitoring genotype–phenotype associations in inflammatory bowel diseases." [11] Abreu also received the 2020 Lifetime Disruptor award from the American College of Gastroenterology. [12]
A large study of more than 2 million people evaluated GLP-1 agonists' benefits and risks. The study showed that GLP-1 agonists reduced risk of substance use and psychotic disorders, seizures, neurocognitive disorders (including Alzheimer’s disease and dementia), coagulation disorders, cardiometabolic disorders, infectious illnesses, and several respiratory conditions. [5]